Supplementary Figure S1 Forest plots for the effect of ipragliflozin on lipid levels: (A) Change in highdensity lipoprotein (HDL) level [mg/dL], (B) Change in low-density lipoprotein (LDL) level [mg/dL], (C) Change in triglycerides level [mg/dL]. Note: NCT#, National Clinical Trial number; 95%CI, 95%Confidence Interval.

Supplementary Figure S2 Forest plots for the risk of hypoglycemia associated with ipragliflozin. Note: NCT#, National Clinical Trial number; 95%CI, 95%Confidence Interval.


Supplementary Figure S3 Forest plots for the risk of genital tract infections (GTI) associated with ipragliflozin. Note: NCT#, National Clinical Trial number; 95%CI, 95%Confidence Interval.

Supplementary Figure S4 Forest plots for the risk of urinary tract infections (UTI) associated with ipragliflozin. Note: NCT#, National Clinical Trial number; 95%CI, 95%Confidence Interval.

Supplementary Figure S5 Forest plots for the risk of skin reactions associated with ipragliflozin. Note: NCT#, National Clinical Trial number; 95%CI, 95%Confidence Interval.


Supplementary Figure S6 Forest plots for the risk of bone fractures associated with ipragliflozin. Note: NCT#, National Clinical Trial number; 95%CI, 95%Confidence Interval.

А




Note: Based on published unadjusted values and may differ from adjusted results

В



Note: Based on published unadjusted values and may differ from adjusted results



Note: Based on published unadjusted values and may differ from adjusted results





Figure S3






Figure S5




Figure S6

